Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-506 first-in-human phase I/IIa study in HRD/FAD solid tumors and oligoprogressive solid tumors on immune checkpoint inhibitors
NL-OMON60751Phase 2Suspended
- Sponsor
- Convert Pharmaceuticals
- Start
- Dec 2022
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cp-506, sponsored by Convert Pharmaceuticals. Started Dec 2022; status: suspended.
02
Drugs
cp-506
Beyond the preview
Go deeper on NL-OMON60751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60751.